- Companies
- Racura Oncology
Racura Oncology Valuation Multiples
Racura Oncology is valued at $275M as of September 2026, a 124.5x revenue multiple. In the last 12 months, Racura Oncology revenue was $2M and Racura Oncology EBITDA was ($3M).
Racura Oncology Overview
About Racura Oncology
Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.
Founded
2011
HQ
Employees
N/A
Website
Financials (LTM)
EV
$251M
Valuation Multiples
Start free trialRacura Oncology Financials
Racura Oncology reported last 12-month revenue of $2M and negative EBITDA of ($3M).
In the same LTM period, Racura Oncology generated ($3M) in EBITDA losses and had net loss of ($8M).
Revenue (LTM)
Racura Oncology P&L
In the most recent fiscal year, Racura Oncology reported revenue of $2M and EBITDA of ($8M).
Racura Oncology is unprofitable as of last fiscal year, with EBITDA margin of (400%) and net margin of (388%).
Financial data powered by Morningstar, Inc.
Racura Oncology Stock Performance
Racura Oncology has current market cap of $275M, and enterprise value of $251M.
Market Cap Evolution
Racura Oncology's stock price is $1.40.
Racura Oncology share price decreased by 8.1% in the last 30 days, and by 32.0% in the last year.
Racura Oncology has an EPS (earnings per share) of $-0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $251M | $275M | -4.0% | -8.1% | -8.2% | -32.0% | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRacura Oncology Valuation Multiples
Racura Oncology trades at 124.5x EV/Revenue multiple, and (73.0x) EV/EBITDA.
EV / Revenue (LTM)
Racura Oncology Financial Valuation Multiples
As of September 25, 2026, Racura Oncology has market cap of $275M and EV of $251M.
Racura Oncology has a P/E ratio of (34.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Racura Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Racura Oncology Margins & Growth Rates
Racura Oncology decreased revenue by 100% but EBITDA grew by 69% in the last fiscal year.
In the most recent fiscal year, Racura Oncology reported EBITDA margin of (400%) and net margin of (388%).
Racura Oncology Margins
Racura Oncology Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Racura Oncology Operational KPIs
Racura Oncology's Rule of 40 is (407%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Racura Oncology's Rule of X is (407%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Racura Oncology Competitors
Racura Oncology competitors include PegBio, Q32 Bio, Dishman Carbogen Amics, Starpharma, Palisade Bio, Duopharma Biotech, Celon Pharma, Northwest Biotherapeutics, Lexeo Therapeutics and Santhera Pharma.
Most Racura Oncology public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | ($31M) | - | - | (7.7x) | - | |||
| $54M | $29M | 3.2x | 11.9x | 6.0x | (7.6x) | |||
| $300M | $60M | 1.6x | - | 8.2x | - | |||
| $8M | ($5M) | 31.4x | 25.2x | (52.8x) | (119.9x) | |||
| - | ($17M) | - | 472.7x | (8.9x) | - | |||
| $228M | $44M | 1.4x | 1.3x | 7.5x | 6.8x | |||
| $48M | $4M | 6.3x | 4.4x | 75.1x | 38.3x | |||
| $1M | ($50M) | 245.6x | - | (6.8x) | (5.5x) | |||
This data is available for Pro users. Sign up to see all Racura Oncology competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Racura Oncology
| When was Racura Oncology founded? | Racura Oncology was founded in 2011. |
| Where is Racura Oncology headquartered? | Racura Oncology is headquartered in Australia. |
| Is Racura Oncology publicly listed? | Yes, Racura Oncology is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Racura Oncology? | Racura Oncology trades under RAC ticker. |
| When did Racura Oncology go public? | Racura Oncology went public in 2016. |
| Who are competitors of Racura Oncology? | Racura Oncology main competitors include PegBio, Q32 Bio, Dishman Carbogen Amics, Starpharma, Palisade Bio, Duopharma Biotech, Celon Pharma, Northwest Biotherapeutics, Lexeo Therapeutics, Santhera Pharma. |
| What is the current market cap of Racura Oncology? | Racura Oncology's current market cap is $275M. |
| What is the current revenue of Racura Oncology? | Racura Oncology's last 12 months revenue is $2M. |
| What is the current revenue growth of Racura Oncology? | Racura Oncology revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Racura Oncology? | Current revenue multiple of Racura Oncology is 124.5x. |
| Is Racura Oncology profitable? | No, Racura Oncology is not profitable. |
| What is the current EBITDA of Racura Oncology? | Racura Oncology has negative EBITDA and is not profitable. |
| What is Racura Oncology's EBITDA margin? | Racura Oncology's last 12 months EBITDA margin is (171%). |
| What is the current EV/EBITDA multiple of Racura Oncology? | Current EBITDA multiple of Racura Oncology is (73.0x). |
| What is the current FCF of Racura Oncology? | Racura Oncology's last 12 months FCF is ($3M). |
| What is Racura Oncology's FCF margin? | Racura Oncology's last 12 months FCF margin is (148%). |
| What is the current EV/FCF multiple of Racura Oncology? | Current FCF multiple of Racura Oncology is (84.1x). |
| How many companies Racura Oncology has acquired to date? | Racura Oncology hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Racura Oncology has invested to date? | Racura Oncology hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Racura Oncology
Lists including Racura Oncology
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




